These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31748628)

  • 1. Similar plasma lipidomic profile in people living with HIV treated with a darunavir-based or an integrase inhibitor-based antiretroviral therapy.
    Mena A; Clavero E; Díaz-Díaz JL; Castro A
    Sci Rep; 2019 Nov; 9(1):17184. PubMed ID: 31748628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study.
    Chaudhary NS; Kind T; Willig AL; Saag MS; Shrestha S; Funderburg N; Wiener HW; Overton ET; Irvin MR
    Medicine (Baltimore); 2021 Jul; 100(30):e26588. PubMed ID: 34397689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
    Quercia R; Roberts J; Martin-Carpenter L; Zala C
    Clin Drug Investig; 2015 Mar; 35(3):211-9. PubMed ID: 25637061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
    Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
    HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
    Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
    AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
    Martinez E; Gonzalez-Cordon A; Ferrer E; Domingo P; Negredo E; Gutierrez F; Portilla J; Curran A; Podzamczer D; Murillas J; Bernardino JI; Santos I; Carton JA; Peraire J; Pich J; Perez I; Gatell JM;
    HIV Med; 2014 Jul; 15(6):330-8. PubMed ID: 24417772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHS.
    Jao J; Balmert LC; Sun S; McComsey GA; Brown TT; Tien PC; Currier JS; Stein JH; Qiu Y; LeRoith D; Kurland IJ
    J Clin Endocrinol Metab; 2022 Jan; 107(1):119-135. PubMed ID: 34498048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients.
    Casado JL; Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Montero M; Mena A; Palacios R; Lopez JC; Vergas J; Galindo MJ; Cabello A; Deltoro MG; Diaz De Santiago A;
    Int J STD AIDS; 2020 Apr; 31(5):467-473. PubMed ID: 32138618
    [No Abstract]   [Full Text] [Related]  

  • 10. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
    Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F
    PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
    Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
    Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
    [No Abstract]   [Full Text] [Related]  

  • 13. Dolutegravir with boosted darunavir as treatment simplification for treatment-experienced HIV patients with multiple mutations.
    Paparizos V; Vasalou V; Kourkounti S
    Int J STD AIDS; 2019 Oct; 30(12):1214-1215. PubMed ID: 31775586
    [No Abstract]   [Full Text] [Related]  

  • 14. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Rodgers A; Lupinacci L; Kumar S; Sklar P; Hanna GJ; Hwang C; Martin EA;
    Lancet HIV; 2020 Jan; 7(1):e16-e26. PubMed ID: 31740348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals.
    Hawkins KL; Montague BT; Rowan SE; Beum R; McLees MP; Johnson S; Gardner EM
    Antivir Ther; 2019; 24(7):513-519. PubMed ID: 31538963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.
    Capetti AF; De Socio GV; Cossu MV; Sterrantino G; Cenderello G; Cattelan A; Baldin GM; Soria A; Riccardi N; Niero FP; Celesia BM; Barbarini G; Rusconi S; Rizzardini G
    HIV Clin Trials; 2018 Dec; 19(6):242-248. PubMed ID: 30890064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrase inhibitor-based regimens are related to favorable systemic inflammatory index and platecrit scores in people living with HIV (PLWH) up to 2 years.
    Şahin EA; Mavi D; Kara E; Sönmezer MÇ; İnkaya AÇ; Ünal S
    Postgrad Med; 2022 Aug; 134(6):635-640. PubMed ID: 35671079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada.
    Wheeler J; Chan S; Harrigan PR; Becker M; Kasper K; Keynan Y
    Int J STD AIDS; 2018 Apr; 29(5):520-522. PubMed ID: 29513131
    [No Abstract]   [Full Text] [Related]  

  • 20. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
    Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
    HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.